8/26/2009 2:30:46 PM
Keele, UK: 26 August 2009, Cobra Biomanufacturing Plc (AIM: CBF), the international manufacturer of biopharmaceuticals, today announces that it has signed an agreement with a European biotechnology company to provide development services for an Adenovirus based product. Cobra was selected because of its experience with Adenovirus production and the full production service that Cobra can provide.
At the heart of the contract will be the application of Cobra’s proprietary virus purification platform, which is based on scalable chromatographic operations and integrates single use technologies throughout. The process shows comparable purities to density gradient approaches and yields of up to 50%.
Simon Saxby, Chief Executive of Cobra Biomanufacturing said: “We are very pleased to have been selected by this company as this underlines Cobra’s extensive experience and expertise in producing virus based products for clinical trials. This agreement also highlights Cobra’s continued commitment to be the CMO of choice for virus production.”
About Cobra Biomanufacturing Plc:
Cobra Biomanufacturing Plc is a leading international manufacturer of biopharmaceuticals to the lifescience industry. Founded in 1992, Cobra provides innovative manufacturing solutions to the biopharmaceutical industry covering DNA, virus, cellular therapeutics and recombinant protein products.
Cobra has developed a range of unique, patented technologies, which underpin a successful revenue generating contract manufacturing business.
This email, its content and any files transmitted with it are confidential and are intended only for the addressee. If you are not the addressee, you may not print, copy, use or rely on the contents, attachments or information in any way except with the express written permission of the sender. If this email has been sent to you in error please destroy it and contact the sender. This email has been prepared using information believed by the author to be reliable and accurate, but College Hill makes no warranty as to its accuracy or completeness.
In particular, College Hill does not accept changes made to this email after it was sent.
comments powered by